Lisata Acquires Marea, $225M Private Placement
Analysis based on 6 articles · First reported Sep 17, 2026 · Last updated Sep 18, 2026
The transaction transforms Lisata into a cardioendocrine-focused company with a substantially larger shareholder base and roughly $225 million in fresh capital, which reduces near-term financing risk but brings heavy dilution to legacy holders. The deal is a modest positive for sentiment around small-cap biotech M&A and specialty pharma financing, with limited broader market spillover.
Lisata Therapeutics acquired Marea Therapeutics, a clinical-stage biotechnology company developing next-generation medicines for cardioendocrine diseases, in a stock-for-stock transaction. All of Marea's outstanding equity interests were exchanged for 1,793,129 shares of Lisata common stock and 211,365.213 shares of Series C non-voting convertible preferred stock, representing in aggregate 213,158,342 shares of Lisata common stock on an as-converted basis. Concurrently, Lisata entered into a definitive purchase agreement for an oversubscribed private placement of Series C non-voting convertible preferred stock expected to raise approximately $225 million in gross proceeds before expenses. Following the transactions, on a fully diluted, as-converted basis, pre-acquisition Lisata equity holders will own approximately 2.39%, Marea equity holders approximately 59.54%, and private placement investors approximately 38.07% of Lisata. Lisata plans to use the net proceeds primarily to advance Marea's lead candidates MAR001/005 for severe hypertriglyceridemia, currently in Phase 2b development, and MAR002 for acromegaly, currently in Phase 2, through key clinical milestones, with topline data from both studies expected in the fourth quarter of 2027. The financing is expected to fund operations into 2028. Lisata will continue evaluating next steps for its existing oncology candidate certepetide while prioritizing Marea's cardioendocrine pipeline. The acquisition was approved by the boards of both companies and Marea's stockholders; the private placement was not subject to Lisata stockholder approval. H.C. Wainwright & Co. advised Lisata and Leerink Partners advised Marea. Lisata shares traded at $1.47 at the previous close on Nasdaq.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard